Replies to post #14229 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, to my knowledge, MVP has only one investment that they have held when it went public, ANIP. They have held it since the merger with BPAX. The equity they gave up in ANIP to BPAX share holders is now valued at close to $165 million and at one time would have been worth over $37 million. They were also a subsidiary of Wells Fargo at the time.

The way I see it, BPAX's initial patent application the reviewer assigned prior art to Dudley's application as it relates to CV event reduction, however Dudley's application was missing supportive data, which ANIP has in spades. Complicating matters was that Dudley's application was in a 50/50 sharing agreement with Besins Healthcare and Abbott/AbbVie.

In relation to Breast Cancer event reduction, ANIP has established prior art in their patent application prosecution on December 19, 2015.

AbbVie also now owns all the Intrinsa data.

Libigel safety and efficacy trial data is due to be posted October 27, 2023 or before.

Hard to believe there is not a master plan tying it all together to maximize profits and sustainability. I envision future patent application(s) to maximize patent coverage.

JMHO